Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 18/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2516681 | 1.00 | TXNRD1 (0.42) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL2516684 | 1.00 | TXNRD1 (0.42) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL5021634 | 0.87 | TXNRD1 (0.46) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL13767339 | 0.85 | TXNRD1 (0.44) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL14358524 | 0.84 | CTSB (0.41) | MAPTMAPK1NPSR1RAB9AHTT | |
| SCHEMBL14358522 | 0.84 | CTSB (0.41) | MAPTMAPK1NPSR1RAB9AHTT | |
| SCHEMBL14358526 | 0.84 | CTSB (0.41) | MAPTMAPK1NPSR1RAB9AHTT | |
| SCHEMBL14048719 | 0.81 | TXNRD1 (0.47) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL2541576 | 0.80 | NNMT (0.36) | — | |
| SCHEMBL2541573 | 0.80 | NNMT (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379554-B1 | NAPHTHYRIDIN-2(1H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2015-11-11 | — | — | EP | disclosed |
| US-8318940-B2 | Naphthyridin-2 (1 H)-one compounds useful as antibacterials | GLAXO GROUP LIMITED (GB) | 2012-11-27 | — | — | US | disclosed |
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2011-12-29 | — | — | US | disclosed |
| EP-2379554-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2011-10-26 | — | — | EP | disclosed |
| EP-2238135-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2010-10-13 | — | — | EP | disclosed |
| WO-2010081874-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010045987-A1 | SUBSTITUTED (AZA) -1-METHYL-1H-QUIN0LIN-2-0NES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010046388-A1 | SUBSTITUTED (AZA) -1-METHYL-1H-QUINOLIN-2-ONES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED | 2010-04-08 | — | — | US | disclosed |
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2137195-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009090222-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
| EP-2080761-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008128953-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319424-A1 | NAPHTHYRIDIN-2(1H) -ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | RIF1, MRPL21, NAT1 | TXNRD1 394/4885S1PR4 4371/4885MAPT 3217/4885 |
| US-20120115899-A1 | NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS | NAT1, RIF1, MRPL21 | TXNRD1 1021/4885S1PR4 4385/4885MAPT 4145/4885 |
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | NRDC, NDC1, NANS | TXNRD1 657/4885S1PR4 4465/4885MAPT 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.